Simons Trading Research

Author: simonsg   |   Latest post: Tue, 27 Oct 2020, 8:56 AM


Riverstone Holdings - a Clean Bill of Health for 2H19F

Author:   |    Publish date:

  • RIVERSTONE (SGX:AP4)’s 1H19 results disappointed slightly, with net profit of RM62.7m at 44%/46% of our and Bloomberg consensus full-year estimates.
  • Nevertheless, we expect earnings recovery in 2H19F, with cleanroom gloves demand picking up and easing competition in healthcare gloves segment.
  • We resume coverage on Riverstone with an ADD call and Target Price of S$1.17, based on 17.0x FY20F P/E.

RSTON’s 2Q19 Results Were a Slight Disappointment

  • Riverstone's 2Q19 revenue grew 11.9% y-o-y, driven by an uptick in demand for both cleanroom and healthcare gloves, although healthcare gloves’ ASP trended lower due to lower raw material costs. GPM contracted 2.4% pts y-o-y due to a shift in product mix and lower ASP; this resulted in a net profit decline of 3.1% y-o-y.
  • We deem 1H19 results slightly below expectations, with net profit coming in at 44%/46% of our/Bloomberg consensus full-year forecasts.
  • Although Riverstone declared a higher interim DPS of RM1.55 (+15% y-o-y), management clarified that this was to offset the lower FY18 final dividend payout. We forecast dividend payout ratio to remain at 40% in FY19F.

Demand for Cleanroom Gloves Picking Up

  • A positive surprise during the analyst briefing was an acceleration in sales growth of cleanroom gloves (25% revenue contribution; 53% GP contribution in 2Q19) to 15-20% y-o-y since Jun, mainly driven by stronger demand from non-HDD manufacturers (FY18: single-digit sales growth).
  • We also expect cleanroom gloves’ GPM to improve in 3Q19, as prices of key raw materials including butadiene (68% of COGS) and acrylonitrile (27% of COGS) fell 34.3% and 17.1% y-o-y respectively in July.

Easing Competition for Healthcare Gloves Segment

  • Healthcare glove segment could also post stronger results in 2H19, in our view, helped by
    1. improved supply-demand dynamics from better absorption of new supply in the Malaysian glove industry, and
    2. tailwinds from weaker ringgit vs. US$.
  • Management noted that pricing competition has eased, and Riverstone has managed to pass half of the additional costs from Jul’s gas tariff hike to customers.
  • Supported by the easier comparison base of 2H18 (which was plagued by volatile raw material price movements and labour shortage), we forecast Riverstone’s GPM to expand by 1.2% pts y-o-y, and net profit to grow 18.2% y-o-y in 2H19F (1H19: -3.0% y-o-y).

Resume Coverage With ADD Rating and Target Price of S$1.17

  • With the expected earnings recovery in 2H19F, we resume coverage with an ADD rating. Our Target Price of S$1.17 is pegged to 17.0x CY20F P/E (Riverstone’s 5-year average historical P/E).
  • At 13.0x FY20F P/E, which represents a 31% discount to Malaysian peers, we deem Riverstone’s valuation undemanding.
  • Potential re-rating catalysts include stronger-than-expected volume growth of cleanroom gloves.
  • Key downside risks include pricing competition leading to a fall in healthcare gloves’ margins.

Source: CGS-CIMB Research - 8 Aug 2019

Share this
Labels: Riverstone

Related Stocks

Chart Stock Name Last Change Volume 
Riverstone 3.65 +0.06 (1.67%) 1,480 

  Be the first to like this.

I3 Messenger
Individual or Group chat with anyone on I3investor

63  97  114  829 

Top 10 Active Counters
 Jiutian Chemical 0.085+0.003 
 Rex Intl 0.145+0.014 
 Aspen 0.26-0.015 
 Sembcorp Marine 0.132+0.003 
 QT Vascular 0.0090.00 
 SoilbuildBizReit 0.465-0.005 
 Medtecs Intl 1.19-0.02 
 CapitaMall Trust 1.84+0.02 
 CFM 0.044+0.001 
 Abundance Intl 0.0380.00